CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of- the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest for themselves (or their spouses/partners) that have been resolved through a peer review process: Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Michelle Paley, MD, Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Chris Thomson, MD and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc. Research To Practice receives education grants from Abraxis Oncology, Amgen Inc, AstraZeneca Pharmaceuticals LP, Biogen Idec, Genentech BioOncology, Genomic Health Inc, Roche Laboratories Inc and Sanofi- Aventis, who have no influence on the content development of our educational activities.

In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:

Dr Swain — No financial interests or affiliations to disclose. Dr Pritchard — Consulting Fees and Speakers Bureau: AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals, Roche Laboratories Inc, Sanofi-Aventis; Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals, Novartis Pharmaceuticals, Roche Laboratories Inc. Dr Piccart-Gebhart — Consulting Fees: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis Pharmaceuticals, Sanofi-Aventis; Grants/Research Support: Bristol-Myers Squibb Company, Novartis Pharmaceuticals, Ortho Biotech Products LP, Roche Laboratories Inc, Sanofi-Aventis. Dr Ravdin — Consulting Fees: AstraZeneca Pharmaceuticals LP, Sanofi-Aventis; Ownership Interest: Adjuvant! Inc. Dr Mackey — Consulting Fees and Speaking Honoraria: Amgen Inc, AstraZeneca Pharmaceuticals LP, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis. Dr Howell — Consulting Fees and Honorarium: AstraZeneca Pharmaceuticals LP; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals. Dr Robert — Consulting Fees: Abraxis Oncology, AstraZeneca Pharmaceuticals LP. Dr Burstein — Speakers Bureau: Amgen Inc, Genentech BioOncology.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.